½ÃÀ庸°í¼­
»óǰÄÚµå
1520688

¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå ±Ô¸ð : Á¦Ç° À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° ¿¹Ãø(2023-2032³â)

Global Xenotransplantation Market Size, By Product Type (Organ Preservation Solution, Transplant Diagnostics, Xeno Products, Others), By Application, By End-use, and Regional Forecasts 2023-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ÀÌÁ¾ÀÌ½Ä ½ÃÀåÀº 2023³â ¾à 299¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2032³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 8.9% ÀÌ»óÀÇ °ß½ÇÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌÁ¾ À̽ÄÀº ÇÑ Á¾¿¡¼­ ´Ù¸¥ Á¾À¸·Î »ì¾ÆÀÖ´Â ¼¼Æ÷, Á¶Á÷ ¶Ç´Â Àå±â¸¦ À̽ÄÇÏ´Â °ÍÀ» Æ÷ÇÔÇϸç ÁÖ·Î À̽Ŀ¡ »ç¿ëÇÒ ¼öÀÖ´Â Àΰ£ Àå±âÀÇ ºÎÁ·À» ÇØ°áÇϱâ À§ÇØ µ¿¹°ÀÇ Àå±â ¶Ç´Â Á¶Á÷À» Àΰ£¿¡°Ô À̽ÄÇÏ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù. ÁÖ¿ä ¸ñÀûÀº ºñÀΰ£ µ¿¹°ÀÇ Àå±â¸¦ »ç¿ëÇÏ¿© Àΰ£ ¼öÇýÀÚÀÇ ¼Õ»óµÇ°Å³ª ±â´É Àå¾Ö°¡ ÀÖ´Â Àå±â¸¦ ´ëüÇϰųª º¹±¸ÇÏ´Â °ÍÀÔ´Ï´Ù. Àå±â À̽Ŀ¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í Àå±â ºÎÁ· À§±â¿¡ ´ëóÇÒ ¼ö ÀÖ´Â ½ÇÇà °¡´ÉÇÑ ÇØ°áÃ¥À¸·Î¼­ ÀÌÁ¾ À̽ÄÀÇ °¡´É¼ºÀº Å« ¼ºÀå ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. Àå±â À̽Ŀ¡ ´ëÇÑ ³ôÀº ¼ö¿ä´Â Àå±â ±âÁõÀÚ ºÎÁ·°ú ÇÔ²² ±ä ´ë±â ½Ã°£°ú »ç¸Á·ü Áõ°¡·Î À̾îÁ® ÀÌÁ¾ ÀÌ½Ä ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, CRISPR-Cas9¿Í °°Àº ±â¼úÀº Àΰ£ ¼öÇýÀÚ¿Í ´õ Àß ¸Â´Â Àå±â¸¦ °¡Áø À¯ÀüÀÚ Á¶ÀÛ µ¿¹°À» ¸¸µé ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á À¯Àü°øÇÐ ¹× Àå±â º¸Á¸ ±â¼úÀÇ ¹ßÀüÀÌ ½ÃÀå ¼ºÀåÀÇ Áß¿äÇÑ ÃËÁøÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ·Îº¿ º¸Á¶ ¼ö¼úÀº ÀÌÁ¾ ÀÌ½Ä ¼ö¼úÀÇ Á¤È®¼º°ú ¾ÈÀü¼ºÀ» Çâ»ó½ÃÄÑ ¼ö¼ú °á°ú¸¦ °³¼±ÇÏ°í ¼ö¼ú ÈÄ ÇÕº´ÁõÀ» ÁÙÀÏ ¼ö ÀÖÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ½ÃÀåÀº ¾ö°ÝÇÑ ±ÔÁ¦ ½Ã³ª¸®¿À¿Í ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·°ú °°Àº ¹®Á¦¿¡ Á÷¸éÇØ ÀÖÀ¸¸ç, ÀÌ´Â ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ¸¸¼ºÁúȯÀÇ ³ôÀº À¯º´·ü, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ, À¯¸®ÇÑ ±ÔÁ¦ Á¤Ã¥À¸·Î ÀÎÇØ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÌÁ¾ ÀÌ½Ä Ã¤Åà Áõ°¡, ÀÌ½Ä ¼ö¼ú °Ç¼ö Áõ°¡, Àå±â ±âÁõ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡·Î ÀÎÇØ ºü¸¥ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå ÁÖ¿ä ¿ä¾à

  • ¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2023-2032³â)
  • Áö¿ªº° °³¿ä
  • ºÎ¹®º° °³¿ä
    • Á¦Ç° À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾ ¿ëµµº°
  • ÁÖ¿ä µ¿Çâ
  • °æ±âÈÄÅðÀÇ ¿µÇâ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È

Á¦2Àå ¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå Á¤ÀÇ¿Í Á¶»çÀÇ ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
    • Æ÷ÇÔ°ú Á¦¿Ü
    • Á¦ÇÑ »çÇ×
    • °ø±ÞÃø ºÐ¼®
      • °¡¿ë¼º
      • ÀÎÇÁ¶ó
      • ±ÔÁ¦ ȯ°æ
      • ½ÃÀå °æÀï
      • °æÁ¦¼º(¼ÒºñÀÚ ½ÃÁ¡)
    • ¼ö¿äÃø ºÐ¼®
      • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
      • ±â¼ú Áøº¸
      • ģȯ°æ
      • ¼ÒºñÀÚ Àǽİú ¼ö¿ë
  • Á¶»ç ¹æ¹ý
  • Á¶»ç ´ë»ó³âµµ
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
  • ½ÃÀå ±âȸ

Á¦4Àå ¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ¹ÙÀ̾îÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
    • Porter's Five Forces ¸ðµ¨¿¡ ´ëÇÑ ¹Ì·¡Àû Á¢±Ù
    • Porter's Five ForcesÀÇ ¿µÇ⠺м®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È

Á¦5Àå ¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¦Ç° À¯Çüº°, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • Àå±â º¸Á¸ ¿ë¾×
    • ÀÌ½Ä Áø´Ü
    • Xeno Products
    • Àå±â
    • ¼¼Æ÷
    • Á¶Á÷
    • ±âŸ

Á¦6Àå ¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµº°, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • ½ÅÀå
    • ½ÉÀå
    • °£
    • Æó
    • ±âŸ

Á¦7Àå ¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • À̽ļ¾ÅÍ
    • º´¿ø
    • ±âŸ

Á¦8Àå ¼¼°èÀÇ ÀÌÁ¾ ÀÌ½Ä ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022-2032³â

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ¿µ±¹
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Àεµ
    • Áß±¹
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Novartis AG
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
      • Á¦Ç° °³¿ä
      • ½ÃÀå Àü·«
    • Immerge BioTherapeutics, Inc.
    • United Therapeutics Corporation
    • Infigen, Inc.
    • eGenesis, Inc.
    • NZeno Limited
    • Preservation Solutions, Inc.
    • Xeno Transplants Corporation
    • F. Hoffmann-La Roche Ltd.
    • OrganOX Limited
    • Tissera, Inc.
    • Lung Biotechnology PBC
    • Enlivex Therapeutics Ltd.
    • United Xenex
    • Biolife4D

Á¦10Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
LSH 24.08.06

The Global Xenotransplantation Market was valued at approximately USD 29.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.9% over the forecast period 2024-2032. Xenotransplantation involves the transplantation of living cells, tissues, or organs from one species to another, primarily focusing on transferring animal organs or tissues into humans to address the shortage of human organs available for transplantation. The primary aim is to utilize non-human animal sources to replace or repair damaged or dysfunctional organs in human recipients. The rising demand for organ transplantation and the potential of xenotransplantation as a viable solution to address the organ shortage crisis will create substantial growth opportunities. The high demand for organ transplants, coupled with the scarcity of organ donors, leads to long waiting times and increased mortality rates, driving the growth of the xenotransplantation market.

Moreover, advancements in genetic engineering and organ preservation technologies are crucial drivers of market growth. Techniques such as CRISPR-Cas9 enable the creation of genetically engineered animals with organs more compatible with human recipients. Additionally, robotic-assisted surgery is anticipated to improve the precision and safety of xenotransplantation procedures, enhancing surgical outcomes and reducing post-operative complications. However, the market faces challenges such as stringent regulatory scenarios and a dearth of skilled professionals, which could impede growth.

The key regions considered for the Global Xenotransplantation Market study include North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America holds the largest market share, driven by the high prevalence of chronic diseases, significant investment in research and development, and favorable regulatory policies. The Asia-Pacific region is expected to witness rapid growth due to the increasing adoption of xenotransplantation, a growing number of transplant procedures, and rising awareness of organ donation.

Major market players included in this report are:

  • Novartis AG
  • Immerge BioTherapeutics, Inc.
  • United Therapeutics Corporation
  • Infigen, Inc.
  • eGenesis, Inc.
  • NZeno Limited
  • Preservation Solutions, Inc.
  • Xeno Transplants Corporation
  • F. Hoffmann-La Roche Ltd.
  • OrganOX Limited
  • Tissera, Inc.
  • Lung Biotechnology PBC
  • Enlivex Therapeutics Ltd.
  • United Xenex
  • Biolife4D

The detailed segments and sub-segment of the market are explained below:

By Product Type:

  • Organ Preservation Solution
  • Transplant Diagnostics
  • Xeno Products
  • Organ
  • Cell
  • Tissue
  • Others

By Application:

  • Kidney
  • Heart
  • Liver
  • Lung
  • Others

By End-use:

  • Transplant Centers
  • Hospitals
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • India
  • China
  • Japan
  • South Korea
  • Australia
  • Rest of Asia-Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of the geographical landscape with country-level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approaches.
  • Analysis of the competitive structure of the market.
  • Demand-side and supply-side analysis of the market.

Table of Contents

Chapter 1. Global Xenotransplantation Market Executive Summary

  • 1.1. Global Xenotransplantation Market Size & Forecast (2023-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Product Type
    • 1.3.2. By Application
    • 1.3.3. By End-use
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Xenotransplantation Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory Frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Xenotransplantation Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Increasing Demand for Tissue and Organ Transplantation
    • 3.1.2. Advancements in Genetic Engineering
    • 3.1.3. Growing Number of Surgical Procedures
    • 3.1.4. High Investment in Research and Development Activities
  • 3.2. Market Challenges
    • 3.2.1. Stringent Regulatory Scenario
    • 3.2.2. Dearth of Skilled Professionals
  • 3.3. Market Opportunities
    • 3.3.1. Advancements in Organ Preservation Technologies
    • 3.3.2. Increasing Adoption of Robotics in Minimally Invasive Surgical Techniques
    • 3.3.3. Growing Integration of Advanced Technologies in Transplantation Procedures

Chapter 4. Global Xenotransplantation Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top Investment Opportunity
  • 4.4. Top Winning Strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Xenotransplantation Market Size & Forecasts by Product Type 2023-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Xenotransplantation Market: Product Type Revenue Trend Analysis, 2023 & 2032 (USD Billion)
    • 5.2.1. Organ Preservation Solution
    • 5.2.2. Transplant Diagnostics
    • 5.2.3. Xeno Products
    • 5.2.4. Organ
    • 5.2.5. Cell
    • 5.2.6. Tissue
    • 5.2.7. Others

Chapter 6. Global Xenotransplantation Market Size & Forecasts by Application 2023-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Xenotransplantation Market: Application Revenue Trend Analysis, 2023 & 2032 (USD Billion)
    • 6.2.1. Kidney
    • 6.2.2. Heart
    • 6.2.3. Liver
    • 6.2.4. Lung
    • 6.2.5. Others

Chapter 7. Global Xenotransplantation Market Size & Forecasts by End-use 2023-2032

  • 7.1. Segment Dashboard
  • 7.2. Global Xenotransplantation Market: End-use Revenue Trend Analysis, 2023 & 2032 (USD Billion)
    • 7.2.1. Transplant Centers
    • 7.2.2. Hospitals
    • 7.2.3. Others

Chapter 8. Global Xenotransplantation Market Size & Forecasts by Region 2023-2032

  • 8.1. North America Xenotransplantation Market
    • 8.1.1. U.S. Xenotransplantation Market
      • 8.1.1.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.1.1.2. Application breakdown size & forecasts, 2023-2032
      • 8.1.1.3. End-use breakdown size & forecasts, 2023-2032
    • 8.1.2. Canada Xenotransplantation Market
      • 8.1.2.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.1.2.2. Application breakdown size & forecasts, 2023-2032
      • 8.1.2.3. End-use breakdown size & forecasts, 2023-2032
    • 8.1.3. Mexico Xenotransplantation Market
      • 8.1.3.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.1.3.2. Application breakdown size & forecasts, 2023-2032
      • 8.1.3.3. End-use breakdown size & forecasts, 2023-2032
  • 8.2. Europe Xenotransplantation Market
    • 8.2.1. France Xenotransplantation Market
      • 8.2.1.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.2.1.2. Application breakdown size & forecasts, 2023-2032
      • 8.2.1.3. End-use breakdown size & forecasts, 2023-2032
    • 8.2.2. Germany Xenotransplantation Market
      • 8.2.2.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.2.2.2. Application breakdown size & forecasts, 2023-2032
      • 8.2.2.3. End-use breakdown size & forecasts, 2023-2032
    • 8.2.3. UK Xenotransplantation Market
      • 8.2.3.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.2.3.2. Application breakdown size & forecasts, 2023-2032
      • 8.2.3.3. End-use breakdown size & forecasts, 2023-2032
    • 8.2.4. Spain Xenotransplantation Market
      • 8.2.4.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.2.4.2. Application breakdown size & forecasts, 2023-2032
      • 8.2.4.3. End-use breakdown size & forecasts, 2023-2032
    • 8.2.5. Italy Xenotransplantation Market
      • 8.2.5.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.2.5.2. Application breakdown size & forecasts, 2023-2032
      • 8.2.5.3. End-use breakdown size & forecasts, 2023-2032
    • 8.2.6. Rest of Europe Xenotransplantation Market
      • 8.2.6.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.2.6.2. Application breakdown size & forecasts, 2023-2032
      • 8.2.6.3. End-use breakdown size & forecasts, 2023-2032
  • 8.3. Asia-Pacific Xenotransplantation Market
    • 8.3.1. India Xenotransplantation Market
      • 8.3.1.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.3.1.2. Application breakdown size & forecasts, 2023-2032
      • 8.3.1.3. End-use breakdown size & forecasts, 2023-2032
    • 8.3.2. China Xenotransplantation Market
      • 8.3.2.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.3.2.2. Application breakdown size & forecasts, 2023-2032
      • 8.3.2.3. End-use breakdown size & forecasts, 2023-2032
    • 8.3.3. Japan Xenotransplantation Market
      • 8.3.3.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.3.3.2. Application breakdown size & forecasts, 2023-2032
      • 8.3.3.3. End-use breakdown size & forecasts, 2023-2032
    • 8.3.4. South Korea Xenotransplantation Market
      • 8.3.4.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.3.4.2. Application breakdown size & forecasts, 2023-2032
      • 8.3.4.3. End-use breakdown size & forecasts, 2023-2032
    • 8.3.5. Australia Xenotransplantation Market
      • 8.3.5.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.3.5.2. Application breakdown size & forecasts, 2023-2032
      • 8.3.5.3. End-use breakdown size & forecasts, 2023-2032
    • 8.3.6. Rest of Asia Pacific Xenotransplantation Market
      • 8.3.6.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.3.6.2. Application breakdown size & forecasts, 2023-2032
      • 8.3.6.3. End-use breakdown size & forecasts, 2023-2032
  • 8.4. Latin America Xenotransplantation Market
    • 8.4.1. Brazil Xenotransplantation Market
      • 8.4.1.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.4.1.2. Application breakdown size & forecasts, 2023-2032
      • 8.4.1.3. End-use breakdown size & forecasts, 2023-2032
    • 8.4.2. Mexico Xenotransplantation Market
      • 8.4.2.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.4.2.2. Application breakdown size & forecasts, 2023-2032
      • 8.4.2.3. End-use breakdown size & forecasts, 2023-2032
    • 8.4.3. Rest of Latin America Xenotransplantation Market
      • 8.4.3.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.4.3.2. Application breakdown size & forecasts, 2023-2032
      • 8.4.3.3. End-use breakdown size & forecasts, 2023-2032
  • 8.5. Middle East & Africa Xenotransplantation Market
    • 8.5.1. Saudi Arabia Xenotransplantation Market
      • 8.5.1.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.5.1.2. Application breakdown size & forecasts, 2023-2032
      • 8.5.1.3. End-use breakdown size & forecasts, 2023-2032
    • 8.5.2. South Africa Xenotransplantation Market
      • 8.5.2.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.5.2.2. Application breakdown size & forecasts, 2023-2032
      • 8.5.2.3. End-use breakdown size & forecasts, 2023-2032
    • 8.5.3. Rest of Middle East & Africa Xenotransplantation Market
      • 8.5.3.1. Product Type breakdown size & forecasts, 2023-2032
      • 8.5.3.2. Application breakdown size & forecasts, 2023-2032
      • 8.5.3.3. End-use breakdown size & forecasts, 2023-2032

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Novartis AG
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Market Strategies
    • 9.3.2. Immerge BioTherapeutics, Inc.
    • 9.3.3. United Therapeutics Corporation
    • 9.3.4. Infigen, Inc.
    • 9.3.5. eGenesis, Inc.
    • 9.3.6. NZeno Limited
    • 9.3.7. Preservation Solutions, Inc.
    • 9.3.8. Xeno Transplants Corporation
    • 9.3.9. F. Hoffmann-La Roche Ltd.
    • 9.3.10. OrganOX Limited
    • 9.3.11. Tissera, Inc.
    • 9.3.12. Lung Biotechnology PBC
    • 9.3.13. Enlivex Therapeutics Ltd.
    • 9.3.14. United Xenex
    • 9.3.15. Biolife4D

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦